Morana Vojnic, MD, MBA, explains how FET-PET imaging's FDA approval is enabling neuro-oncologists to identify ...

Perioperative enfortumab vedotin plus pembrolizumab had a cost-effectiveness ratio of $72,460 per QALY vs radical cystectomy ...

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, discusses how Breakthrough Therapy Designation and ...

Targeted Onc connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

FDA final guidance sets a risk-based potency assurance roadmap for cell and gene therapies, spanning development, ...

CT, mouse, and bronchoscopy data link higher body fat to increased lung cancer risk, implicating regulatory T cells as a prevention target. In an interview with Targeted Onc™, Sai Yendamuri, MD, MBA, ...

SABR had higher 3-year all-cause mortality than surgery in early-stage NSCLC (30.3% vs 21.6%) in an emulated target trial; ...

Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.

Dirk Schadendorf, MD, discusses where triplet therapy fits for BRAF V600-mutant melanoma following the results of the STARBOARD trial.

Estelamari Rodriguez, MD, MPH, Julia K. Rotow, MD, and Ana I. Velázquez Mañana, MD, MSc, explain how they choose among guideline-preferred ROS1 tyrosine kinase inhibitors (TKIs) for first-line ...

Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.

Updated ENZARAD findings show no significant metastasis-free survival benefit with enzalutamide, although patients receiving pelvic lymph node radiation may benefit from intensification.